These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 1378994)

  • 1. GnRH agonists and prostate cancer.
    Dreicer R
    Am Fam Physician; 1992 Aug; 46(2):374-6. PubMed ID: 1378994
    [No Abstract]   [Full Text] [Related]  

  • 2. Leuprolide for prostate cancer.
    Med Lett Drugs Ther; 1985 Aug; 27(694):71-2. PubMed ID: 2410765
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
    Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
    Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Male breast cancer during treatment with leuprolide for prostate cancer.
    Yacoub J; Richardson C; Farmer M; Lee WR; Clark PE; Hurt G; Levine EA
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):555-6; discussion 556-7. PubMed ID: 17679929
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonists: gonadorelin, leuprolide and nafarelin.
    Pace JN; Miller JL; Rose LI
    Am Fam Physician; 1991 Nov; 44(5):1777-82. PubMed ID: 1835275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
    Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
    Smith MR; Boyce SP; Moyneur E; Duh MS; Raut MK; Brandman J
    J Urol; 2006 Jan; 175(1):136-9; discussion 139. PubMed ID: 16406890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 15. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
    Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B
    BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201
    [No Abstract]   [Full Text] [Related]  

  • 16. Response of hormone refractory prostate cancer to lycopene.
    Matlaga BR; Hall MC; Stindt D; Torti FM
    J Urol; 2001 Aug; 166(2):613. PubMed ID: 11458084
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leupoprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-8.
    Koupparis AJ
    Eur Urol; 2006 Sep; 50(3):626-7. PubMed ID: 16750291
    [No Abstract]   [Full Text] [Related]  

  • 18. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 19. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.